ClinicalTrials.gg
RecruitingNCT07081464ONDINE-LCUpdated Nov 6, 2026

Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)

An observational study in Ondine Syndrome (Congenital Central Hypoventilation Syndrome), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 7 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
25
Ages
7 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Sleep Apnea, Central with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Sleep Apnea, Central · France.

Started
2025
the only one that year
Observational
8 of 14
3 open now
Registered
14th of 14
by date
Lead sponsor
4 of 14
Assistance Publique - Hôpitaux de Paris

Among the 14 studies in Sleep Apnea, Central with a site in France, this one is the only one that started in 2025, is one of 8 observational ones, and was the 14th registered.

Sleep Apnea, Central

96 studies on the registry are indexed under Sleep Apnea, Central; 18 are open to participants now.

Browse Sleep Apnea, Central studies →

Open to participants now

3 of the 14 studies in Sleep Apnea, Central with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 13 Sleep Apnea, Central studies recruiting now, 8 (62%) set no upper age limit and 3 (23%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 7 Years to 20 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sleep Apnea, Central with a site in France, or all of them as a file.
02

Study summary

This study investigates whether cognitive dysfunction in young patients with congenital central hypoventilation syndrome (Ondine Syndrome) is related to the severity of the disease and dysfunction of the locus coeruleus (a brainstem structure involved in autonomic control and cognition). The investigators will assess cognitive evoked potentials (P300 wave) using high-resolution EEG during attention tasks, pupillometry, brain MRI, neuropsychological tests, and heart rate variability. Patients with different severities of PHOX2B gene mutation (alanine expansions \<27 vs. ≥27) will be compared.

Read the detailed description

Ondine Syndrome (congenital central hypoventilation syndrome) is a rare autosomal dominant genetic disorder caused by mutations in PHOX2B. Patients require lifelong nocturnal ventilation and often have cognitive impairments. The cause of cognitive deficits is uncertain: possible hypoxic brain injury or direct effects of PHOX2B mutations on brain regions like the locus coeruleus.

This cross-sectional study includes 21 patients aged 7-20 years with Ondine Syndrome and PARM-type (polyalanine repeat mutation) PHOX2B mutations, divided into moderate (\<27 alanine expansions) and severe (≥27 expansions) groups. During routine hospitalization, participants undergo:

High-resolution EEG with evoked potentials during auditory and visual attention tasks to measure P300 wave amplitude.

Pupillometry during the same tasks to assess locus coeruleus function.

3T (3 Tesla magnetic resonance imaging) MRI (anatomical and diffusion imaging) without sedation.

Neuropsychological assessment with the Vineland test.

Holter ECG to analyze heart rate variability.

The goal is to link locus coeruleus dysfunction to disease severity and explore its impact on cognition, autonomic balance, and sleep."

03

Conditions studied

  • Ondine Syndrome (Congenital Central Hypoventilation Syndrome)

Keywords

  • Locus Coeruleus
  • PHOX2B
  • Cognitive Dysfunction
  • EEG
  • Pupillometry
  • MRI
  • Ondine Syndrome
04

Who can participate

Ages eligible
7 Years to 20 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Minors and young adults aged 7 to 20 years diagnosed neonatally with Ondine Syndrome, carrying a PARM-type PHOX2B mutation and requiring nocturnal ventilation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonatal diagnosis of Ondine Syndrome.
  • PARM-type PHOX2B mutation.
  • Age 7 to 20 years.
  • Receiving nocturnal ventilation.
  • Consent obtained. Affiliated with social security.

Exclusion criteria

Exclusion Criteria:

  • Severe autism spectrum disorder preventing test completion.
  • Legal guardianship or curatorship.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
25 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjects with severe Ondine syndrome (PHOX2B mutation with ≥ 27 alanine expansions)

    Other: MRI, EEG, Pupillometry

  • Subjects with moderate Ondine syndrome (PHOX2B mutation with < 27 alanine expansions);

    Other: MRI, EEG, Pupillometry

Interventions

  • OtherMRI, EEG, Pupillometry

    Comparison of P300 wave amplitude, pupillometric responses, functional and structural brain connectivity, socio-adaptive function, cardiac autonomic balance between two phenotypic severity groups of young patients with Ondine Syndrome.

06

What researchers measure

Primary outcomes

  1. Amplitude of the P300 wave (peak-to-baseline) recorded by high-resolution EEG during visual and auditory attention tasks.

    Measurement of cognitive evoked potential P300 amplitude using a 64-electrode EEG system during Flanker and oddball paradigms to assess locus coeruleus function.

    Time frame: 24 hours

Secondary outcomes

  1. Ratio of maximal pupil diameter during attention tasks to resting pupil diameter measured by pupillometry.

    Time frame: 24 hours

  2. Functional connectivity parameters of the locus coeruleus measured by high-resolution EEG and 3T brain MRI diffusion imaging.

    Time frame: 24 hours

  3. Scores of socio-adaptive behavior from the Vineland neuropsychological test (Vineland Adaptative Behavior Scales II, with scores ranging from 20 to 160; higher scores indicating better functioning).

    Vineland Adaptative Behavior Scales II, with scores ranging from 20 to 160; higher scores indicating better functioning.

    Time frame: 24 hours

  4. Heart rate variability parameters from Holter ECG monitoring.

    Time frame: 24 hours

  5. Structural connectivity parameters of the locus coeruleus measured by high-resolution EEG and 3T brain MRI diffusion imaging.

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Oct 2025 → Nov 2025, primary completion Oct 2027 → Nov 2027 and completion Oct 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 23, 2025
StartActual
Nov 15, 2025was Oct 2025
Primary completionEst.
Nov 15, 2027was Oct 2027
CompletionEst.
Nov 15, 2027was Oct 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Robert Debré Hospital is now Recruiting
Nov 6, 2026
Start date
Oct 15, 2025→Nov 15, 2025 (actual)
Nov 6, 2026
Primary completion
Oct 15, 2027→Nov 15, 2027
Nov 6, 2026
Study completion
Oct 15, 2027→Nov 15, 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Robert Debré Hospital is now Recruiting
    Start date Oct 15, 2025→Nov 15, 2025 (now actual)
    Primary completion Oct 15, 2027→Nov 15, 2027
    Study completion Oct 15, 2027→Nov 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07081464
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Nov 15, 2025
Primary completion
Nov 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

François-Xavier MAUVAIS, MD, PhD
Contact
francois-xavier.mauvais@aphp.fr
+33140038245
Christophe DELCLAUX, MD, PhD
Contact
christophe.delclaux@aphp.fr
+33140038245
François-Xavier MAUVAIS, MD, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion